Protocol Chair(s)
Balkus, Jen (Protocol Co-Chair)
Noguchi, Lisa (Protocol Co-Chair)
Owor, Maxensia (Protocol Chair)
Mother-infant Pair Study of Dapivirine Ring in Breastfeeding
Protocol Chair(s)
Bunge, Katherine (Protocol Chair)
Fairlie, Lee (Protocol Co-Chair)
Muhlanga, Felix (Protocol Chair)
Safety and PK of Dapivirine VR and PrEP in Pregnancy
Protocol Chair(s)
Liu, Albert (Protocol Chair)
MTN-028 is a Phase I study that seeks to evaluate the safety and systemic and local pharmacokinetics (PK) of vaginal rings (VRs) containing varying dose strengths of the antiretroviral (ARV) drugs Vicriviroc (MK-4176) and MK-2048. The study will enroll approximately 18 women at one U.S. site beginning in mid to late 2015 and will take approximately 6-9 months to conduct.
Protocol Chair(s)
Hoesley, Craig (Protocol Chair)
MTN-027 is a Phase I study that seeks to evaluate the safety and systemic and local pharmacokinetics (PK) of vaginal rings (VRs) containing (1) the antiretroviral (ARV) drug Vicriviroc (MK-4176); (2) the ARV drug MK-2048; or (3) the two ARV drugs in combination. The study will enroll pproximately 48 women at two U.S. sites in mid to late 2015 and will take approximately 6-9 months to conduct.
Protocol Chair(s)
Chen, Beatrice (Protocol Chair)
Study of Dapivirine Vaginal Ring (VR) in a Post-Menopausal Female Population
Protocol Chair(s)
Celum, Connie (Protocol Co-Chair)
Nair, Gonasagrie (Lulu) (Protocol Chair)
Ngure, Kenneth (Protocol Co-Chair)
Email Groups
Primary Objectives
Primary Objectives
Primary Objectives
Acceptability of a Dapivirine VR and PrEP during Pregnancy and Breastfeeding